Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Hhs Ai Strategy topic
No spam. Unsubscribe anytime.
HHS announces departmentwide AI strategy and internal LLM deployments
Summary
Deputy Secretary Jim O'Neil said HHS is launching an "HHS AI Strategy," has deployed custom large language models to departmental staff, and will direct research and regulatory clarity toward using AI to improve drug approvals, fraud detection, claims processing and grant reviews.
Deputy Secretary Jim O'Neil told attendees that HHS is launching an "HHS AI Strategy" to accelerate internal operations and to support safe, effective AI use across health agencies. O'Neil said HHS made a custom large language model available to "all 65,000 employees" and added a second competing model the day before the event to improve productivity across the department.
O'Neil framed the strategy around three priorities: exploring reimbursement pathways that let innovators scale, providing regulatory clarity for safe AI tools at FDA, ONC and CMS, and directing federal R&D toward high‑impact problems such as early detection and chronic disease management. "We're all in on AI," O'Neil said, noting HHS aims to lead on AI rather than follow.
Officials tied the AI strategy to broader efforts: the Access model to test reimbursement for technology‑enabled care, FDA initiatives such as TEMPO for device pilots, and internal uses to speed approvals and streamline grant and claims reviews. O'Neil said the department will balance innovation with patient protections, including de‑identification and transparency in data use.
Ending: O'Neil closed by emphasizing partnership between HHS, CMS, FDA, professional societies and the private sector to deploy AI and other technologies that improve outcomes and reduce costs.
